The 13th Annual Conference on Drug Toxicology, co hosted by the Drug Toxicology and Safety Evaluation Professional Committee of the Chinese Society of Toxicology and organized by the Yangtze River Delta National Technology Innovation Center (Zhejiang), was grandly held at the Nanhu Hotel in Jiaxing, Zhejiang from September 11th to 13th.

As a research enterprise dedicated to preclinical safety research of new drugs, the Shandong Xinbo research team was invited to attend the conference. Company researchers Li Yan, Xing Shanshan, and Song Jinrui gave special presentations at three sub sessions: "Drug Toxicity Pathology Research," "Evaluation of Innovative Drugs such as CGT," and "Drug Mutability and Carcinogenicity Research.

    Annual Meeting Achievements and Future Prospects    

The theme of this year's conference is "AInnovative Medicine, Safety Navigator", which brings together top experts and scholars in the fields of toxicology, drug safety evaluation, and innovative drug development at home and abroad. The conference focuses on cutting-edge hotspots such as innovative drug evaluation, mutagenicity and carcinogenicity research, and new technologies in toxicology and pathology.   

At this annual conference, three researchers, with solid academic foundations and sharp research perspectives, engaged in high-level academic exchanges with toxicology researchers across the country on key issues and the latest developments in the field of toxicology. They jointly explored the future direction of innovative drug safety evaluation, showcased the company's new achievements in animal models, histopathological sections, lesion identification, and dose-response relationships, as well as its profound accumulation in CGT product evaluation, mutagenicity, and carcinogenicity research. Through in-depth interaction with leading scholars, experts, and regulatory agencies in the industry, Shandong Xinbo has gained a clearer understanding of new innovative drugs, risk assessment standards, and regulatory trends.

    山东欣博实力与追求    

Shandong Xinbo will take this annual meeting as an opportunity to continue to deepen the research on innovative drug safety evaluation, closely follow the trend of CGT and biopharmaceutical development, actively explore carcinogenic and mutagenic mechanisms, and enhance the ability to identify and evaluate toxicity pathology. Adhere to the belief of "safety navigation" and continuously provide more refined and reliable safety evaluation services for drug developers.

Shandong Xinbo will work together with the national toxicology community to lead innovation, prioritize safety, and protect people's health with the light of technology. Continuously advancing on the path of new drug research and safety evaluation, jointly writing a new chapter in China's pharmaceutical industry!